Cargando…

Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial

AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function te...

Descripción completa

Detalles Bibliográficos
Autores principales: Komócsi, András, Merkely, Béla, Hadamitzky, Martin, Massberg, Steffen, Rizas, Konstantinos D, Hein-Rothweiler, Ralph, Gross, Lisa, Trenk, Dietmar, Sibbing, Dirk, Aradi, Dániel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627813/
https://www.ncbi.nlm.nih.gov/pubmed/37015874
http://dx.doi.org/10.1093/ehjcvp/pvad027
_version_ 1785131609098289152
author Komócsi, András
Merkely, Béla
Hadamitzky, Martin
Massberg, Steffen
Rizas, Konstantinos D
Hein-Rothweiler, Ralph
Gross, Lisa
Trenk, Dietmar
Sibbing, Dirk
Aradi, Dániel
author_facet Komócsi, András
Merkely, Béla
Hadamitzky, Martin
Massberg, Steffen
Rizas, Konstantinos D
Hein-Rothweiler, Ralph
Gross, Lisa
Trenk, Dietmar
Sibbing, Dirk
Aradi, Dániel
author_sort Komócsi, András
collection PubMed
description AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after percutaneous coronary intervention. METHODS AND RESULTS: Patients were randomized to prasugrel (control group) or a platelet function testing-guided regimen with clopidogrel or prasugrel defined after 1-week clopidogrel. The primary endpoint was the net clinical benefit [cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 2–5 bleeding] for 12 months. Overweight was defined as a body mass index >25 kg/m(2). Patients without overweight showed a significant net clinical benefit from the de-escalation strategy, while in overweight cases de-escalation was comparable to prasugrel treatment [hazard ratio (HR): 0.52; 95% confidence interval (CI): 0.31–0.88; P = 0.013 and HR: 0.95; 95% CI: 0.69–1.31, P = 0.717, P-non-inferiority = 0.03, respectively, P-interaction = 0.053]. The benefit of de-escalation in terms of the risk of bleeding or of the ischaemic events did not reach statistical significance. Bleeding events with de-escalation were less frequent in non-overweight patients but comparable in overweight patients (HR: 0.55; 95% CI: 0.30–1.03; P = 0.057 and HR: 0.95; 95% CI: 0.64–1.41, respectively, P-interaction = 0.147). Non-overweight patients had lower ischaemic event rates with de-escalation, while overweight cases had slightly less (HR: 0.47; 95% CI: 0.18–1.25; P = 0.128 and HR: 0.89; 95% CI: 0.53–1.50, respectively, P-interaction = 0.261). CONCLUSION: The strategy of guided dual antiplatelet therapy de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients.
format Online
Article
Text
id pubmed-10627813
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106278132023-11-08 Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial Komócsi, András Merkely, Béla Hadamitzky, Martin Massberg, Steffen Rizas, Konstantinos D Hein-Rothweiler, Ralph Gross, Lisa Trenk, Dietmar Sibbing, Dirk Aradi, Dániel Eur Heart J Cardiovasc Pharmacother Original Article AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after percutaneous coronary intervention. METHODS AND RESULTS: Patients were randomized to prasugrel (control group) or a platelet function testing-guided regimen with clopidogrel or prasugrel defined after 1-week clopidogrel. The primary endpoint was the net clinical benefit [cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 2–5 bleeding] for 12 months. Overweight was defined as a body mass index >25 kg/m(2). Patients without overweight showed a significant net clinical benefit from the de-escalation strategy, while in overweight cases de-escalation was comparable to prasugrel treatment [hazard ratio (HR): 0.52; 95% confidence interval (CI): 0.31–0.88; P = 0.013 and HR: 0.95; 95% CI: 0.69–1.31, P = 0.717, P-non-inferiority = 0.03, respectively, P-interaction = 0.053]. The benefit of de-escalation in terms of the risk of bleeding or of the ischaemic events did not reach statistical significance. Bleeding events with de-escalation were less frequent in non-overweight patients but comparable in overweight patients (HR: 0.55; 95% CI: 0.30–1.03; P = 0.057 and HR: 0.95; 95% CI: 0.64–1.41, respectively, P-interaction = 0.147). Non-overweight patients had lower ischaemic event rates with de-escalation, while overweight cases had slightly less (HR: 0.47; 95% CI: 0.18–1.25; P = 0.128 and HR: 0.89; 95% CI: 0.53–1.50, respectively, P-interaction = 0.261). CONCLUSION: The strategy of guided dual antiplatelet therapy de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients. Oxford University Press 2023-04-04 /pmc/articles/PMC10627813/ /pubmed/37015874 http://dx.doi.org/10.1093/ehjcvp/pvad027 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Komócsi, András
Merkely, Béla
Hadamitzky, Martin
Massberg, Steffen
Rizas, Konstantinos D
Hein-Rothweiler, Ralph
Gross, Lisa
Trenk, Dietmar
Sibbing, Dirk
Aradi, Dániel
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
title Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
title_full Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
title_fullStr Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
title_full_unstemmed Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
title_short Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
title_sort impact of body mass on p2y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the tropical-acs trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627813/
https://www.ncbi.nlm.nih.gov/pubmed/37015874
http://dx.doi.org/10.1093/ehjcvp/pvad027
work_keys_str_mv AT komocsiandras impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT merkelybela impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT hadamitzkymartin impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT massbergsteffen impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT rizaskonstantinosd impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT heinrothweilerralph impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT grosslisa impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT trenkdietmar impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT sibbingdirk impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial
AT aradidaniel impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial